Sildenafil dose in pphn in 1 day baby
Reading File
Checking Date & Time
Finding Sources
Searching PubMed
sildenafil PPHN neonate newborn dosing
Finding Sources
Searching PubMed
sildenafil "persistent pulmonary hypertension" newborn
Finding Sources
Reading Article
Reading Article
Finding Sources
Finding Sources
Reading File
I now have enough information to provide a comprehensive answer. Here is the summary:
Sildenafil in PPHN — Day 1 Neonate
Why Sildenafil?
Sildenafil is a PDE-5 inhibitor that prevents breakdown of cGMP, potentiating nitric oxide–mediated pulmonary vasodilation. It is used as adjuvant/alternative therapy when inhaled nitric oxide (iNO) is unavailable (the only FDA-approved agent for PPHN).
Dose (Oral/Enteral)
| Parameter | Recommendation |
|---|---|
| Route | Oral / nasogastric (IV formulation rarely used in neonates) |
| Dose | 0.5–1 mg/kg/dose (starting dose; some protocols use up to 2 mg/kg/dose) |
| Frequency | Every 6–8 hours (q6h–q8h) |
| Usual range | 1–3 mg/kg/dose q6–8h (as used in trials) |
In a 2024 network meta-analysis (Fei et al., Crit Care Med 2024, PMID 38363176, 23 RCTs, 902 neonates), the most effective PPHN treatment was iNO + oral sildenafil 1–3 mg/kg/dose q6–8h. When iNO is unavailable, sildenafil + milrinone was ranked second best.
A 2024 RCT (Kallimath et al., BMC Pediatrics, PMID 39487423) used oral sildenafil in term/late-preterm neonates with PPHN and showed significantly faster reduction in pulmonary artery systolic pressure vs. bosentan (median 36h vs. 96h).
Important Considerations in a 1-Day-Old
| Point | Detail |
|---|---|
| Age caution | Sildenafil is off-label in neonates. Use with careful monitoring. |
| FDA warning | The FDA issued a warning against sildenafil in pediatric PAH (children 1–17 years) at higher doses due to increased mortality — this is separate from neonatal PPHN and should not preclude short-term neonatal use. |
| Systemic hypotension | Major risk. Monitor BP closely. Start at the lower end (0.5–1 mg/kg/dose). |
| Hepatic metabolism | Immature CYP3A4 in neonates — half-life is prolonged; q8h dosing preferred on day 1. |
| Availability | Oral sildenafil can be compounded as a 1 mg/mL suspension for neonatal use. |
| Combination | Most effective when used alongside iNO; if no iNO, consider adding milrinone. |
Practical Approach for a 1-Day-Old with PPHN
- First-line: iNO at 20 ppm (if available) + optimize ventilation
- Add sildenafil: 0.5–1 mg/kg PO/NG q8h, increase to q6h if tolerated and response is partial
- Monitor: SpO2, pre/post-ductal saturations, echo (PASP), BP
- Escalate: If refractory → milrinone IV, ECMO
Sources: Barash's Clinical Anesthesia 9e; Fei et al., Crit Care Med 2024 [PMID 38363176]; Kallimath et al., BMC Pediatrics 2024 [PMID 39487423]
⚠️ Always verify doses against your institutional neonatal formulary (e.g., Neofax/Lexicomp) and consult a neonatologist before administration.
This is a shared conversation. Sign in to Orris to start your own chat.